Statin Associated Muscular Adverse Effects.

Area of Science:

• Pharmacovigilance
• Clinical Pharmacology
• Cardiovascular Disease Management

Background:

• Statins are primary treatments for hyperlipidemia and cardiovascular disease prevention.
• A known risk of statin therapy includes muscular adverse effects, ranging from elevated creatine kinase to rhabdomyolysis.

Purpose of the Study:

• To characterize the epidemiological and clinical profiles of patients experiencing statin-associated muscular adverse effects.
• To analyze the spectrum and timeline of these adverse events.

Main Methods:

• Retrospective, descriptive study conducted over a decade (2010-2019).
• Inclusion of all statin-associated muscular adverse effect cases reported to the Tunisian National Centre of Pharmacovigilance.
• Data analysis of patient demographics, symptom presentation, and outcomes.

Main Results:

• 22 cases of statin-associated muscular adverse effects were identified, representing 28% of all statin adverse events.
• The mean patient age was 58.7 years, with a sex ratio of 1.6.
• Manifestations included isolated creatine kinase elevation (12 cases), myalgia (5), myopathy (3), myositis (1), and rhabdomyolysis (1).
• Adverse effects appeared between 7 days and 15 years post-initiation; withdrawal led to symptom resolution within 10 days to 18 months, though creatine kinase remained elevated in 7 cases.
• Atorvastatin, simvastatin, rosuvastatin, and fluvastatin were the implicated statins.

Conclusions:

• Prompt identification of muscle symptoms is essential to avert severe outcomes like rhabdomyolysis.
• Further investigation is necessary to fully understand the mechanisms behind statin-induced muscle damage.